Author: Fiona Craig

  • Airbus Delivers 72 Jets in November, Leaving a Heavy Lift for December Target

    Airbus Delivers 72 Jets in November, Leaving a Heavy Lift for December Target

    Airbus (EU:AIR) reported on Friday that it handed over 72 aircraft in November, bringing total deliveries for 2025 to 657 jets. The latest monthly tally follows what CEO Guillaume Faury called a weak period due to an industrial issue that temporarily disrupted operations.

    With only one month left in the year, Airbus now needs to deliver 133 aircraft in December to meet its revised full-year goal of 790 planes. Hitting that figure would require one of the highest monthly delivery rates in the company’s history as it continues working through the production hurdles that have weighed on output throughout 2025.

  • Quantum Blockchain Technologies Advances Commercial Plans Through New ASIC Partnerships

    Quantum Blockchain Technologies Advances Commercial Plans Through New ASIC Partnerships

    Quantum Blockchain Technologies (LSE:QBT) said Friday that it has entered non-disclosure agreements with three ASIC manufacturers, marking a key step in its strategy to bring its Bitcoin mining software products to market.

    Under the agreements, each manufacturer will provide QBT’s Milan-based testing team with access to their mining rigs as well as their source code. This will enable the company to install the software version of its Method C AI Oracle—first introduced on November 12—directly onto third-party hardware.

    QBT previously began joint analysis of the hardware variant of Method C AI Oracle with one of these ASIC partners, a collaboration first disclosed on April 8. However, because integrating the hardware version into ASIC chip architecture could take as long as 18 months, both sides agreed to prioritize the software implementation to accelerate potential commercialization.

    The company also signed a separate NDA with a Bitcoin mining pool, with the goal of helping the pool’s nodes produce “better quality hash rates” and mine more Bitcoin. This method may allow QBT to avoid installing modified operating systems across every rig connected to that pool.

    On the intellectual property front, QBT said it is working with patent counsel to address examiner questions in Europe and the U.S., describing the process as routine for active applications. The firm is also collaborating with a startup that builds solutions based on Blockscale Intel ASICs to evaluate its Methods A, B, and C across multiple SHA-256 architectures.

    CEO and Executive Chairman Francesco Gardin said: “The Company is now engaged with the ASIC manufacturers it has been targeting over the past year. The Board believe QBT’s technology proposition is unique within the Bitcoin industry, which is the main reason why there is such a high level of interest from mining companies assessing our technology.”

  • Big Yellow Shares Drop After Blackstone Walks Away from Potential Takeover

    Big Yellow Shares Drop After Blackstone Walks Away from Potential Takeover

    Big Yellow Group PLC (LSE:BYG) saw its shares slip 5.3% on Friday after Blackstone Europe confirmed it would not move forward with a takeover bid for the self-storage operator.

    The announcement came shortly after Big Yellow stated on Dec. 4 that it had determined there was “no basis to continue discussions” with Blackstone and therefore would not extend the put-up-or-shut-up deadline of Dec. 8, 2025.

    In its own regulatory update, Blackstone said it has no intention of making an offer for the company, triggering Rule 2.8 restrictions under the City Code on Takeovers and Mergers. However, the firm noted that it may set aside these restrictions under specific scenarios — including with the consent of Big Yellow’s board, if a third party announces a firm intention to bid, if Big Yellow launches a Rule 9 waiver or reverse takeover, or if the Takeover Panel determines that circumstances have materially changed.

    Rothschild & Co is advising Blackstone on the matter.

    The end of takeover discussions has weighed on Big Yellow’s shares, removing acquisition-driven speculation that had supported the stock and prompting investors to reassess the company’s outlook as it continues independently.

  • Greggs Shares Jump After JPM Begins Coverage with “Overweight” Rating

    Greggs Shares Jump After JPM Begins Coverage with “Overweight” Rating

    Shares in Greggs (LSE:GRG) surged more than 5% after J.P. Morgan initiated coverage of the UK food-to-go chain with an “overweight” rating and a December 2027 price target of 2,110p. The target implies roughly 35% upside from the stock’s 1,590p closing level on Dec. 4. The bank pointed to a valuation sitting at cyclical lows despite what it calls best-in-class operating performance and multiple catalysts for recovery.

    According to the note, J.P. Morgan’s investment thesis rests on three core themes: the company’s structurally strong unit economics; a reset valuation following a 40% year-to-date share price decline versus a 15% cut to consensus earnings; and the potential for both earnings and free cash flow to turn sharply higher from fiscal 2026 as fresh distribution capacity ramps up.

    The analysts highlighted that Greggs is currently trading at around a 40% discount to its 10-year average multiples across P/E, EV/EBITDA, and EV/Sales, while also sitting below valuation levels seen at UK supermarkets and peers such as B&M, Zabka, and Domino’s UK.

    J.P. Morgan describes Greggs — a vertically integrated bakery and food-to-go operator — as a “structural winner,” emphasizing its 61.7% gross margin in 2024, nearly double the 30–35% range reported by comparable retailers. The team credits the company’s margin strength to its in-house production model and streamlined product assortment.

    The broker also cited standout productivity metrics: sales densities of £769 per square foot and underlying profit of £162 per square foot, placing Greggs ahead of most discounters and convenience operators and trailing only Aldi and Sainsbury’s convenience formats on profitability per square foot. Return on invested capital is above 20%, which the analysts view as among the strongest in the sector.

    J.P. Morgan’s base-case outlook assumes company-managed like-for-like sales growth of 2.3% in 2025 and 2.5% in 2026, rising toward 3–3.5% in subsequent years. Gross margins are forecast at 61.2% for 2026–27, with gradual improvement to 61.8%. Underlying EBIT margins are expected to climb from 8.4% in 2025 to 8.5% in 2027, approaching 9.8% by 2030. Diluted underlying EPS is projected to grow from 117.23p in 2025 to 236.68p in 2032.

    Management guidance suggests elevated capital expenditure through 2026 as new distribution hubs in Derby and Kettering are built out, with a peak of £300 million in 2025 before capex trends back toward roughly 6% of revenue. Free cash flow, which is anticipated to be negative £64 million in 2025, is projected to rebound to £109 million in 2027, £205 million in 2029, and £228 million by 2032.

    The analysts expect the new distribution centres to enhance national capacity and underpin Greggs’ plan to increase its store base from 2,618 to 3,000 by 2030. They also argued that peak investment should not be mistaken for a long-term rise in capital intensity and noted management’s confidence in substantial remaining “white space” with minimal cannibalisation risk.

    Additional growth drivers flagged by J.P. Morgan include the company’s expanding evening-trade contribution—which now exceeds 9% of company-managed sales—as well as continued momentum in digital ordering and delivery channels.

    J.P. Morgan’s scenario analysis assigns a bull-case valuation of 2,430p, implying up to 53% upside, while its bear-case target of 1,340p suggests 16% potential downside. The firm said this range reflects an asymmetric risk-reward profile tilted in favour of further gains.

  • SkinBioTherapeutics Delivers Major Revenue Growth and Broadens Strategic Footprint in 2025

    SkinBioTherapeutics Delivers Major Revenue Growth and Broadens Strategic Footprint in 2025

    SkinBioTherapeutics (LSE:SBTX) has reported a strong set of full-year results for 2025, highlighted by a 284% surge in revenue to £4.6 million. Growth was fueled by rising direct sales and expanding royalty income tied to its AxisBiotix™ and Dermatonics product lines. During the year, the company completed a commercial partnership with Croda and launched Zenakine™ into the global cosmetics market, while also extending its retail reach through an exclusive distribution agreement with Superdrug Stores plc. The acquisitions of Bio-Tech Solutions and Dermatonics have strengthened both production capacity and financial performance, reinforcing SkinBioTherapeutics’ position within the growing skin health sector.

    Despite these operational gains, the company continues to face meaningful financial pressures. Ongoing losses and cash burn weigh heavily on its stock assessment, and technical signals remain bearish. Although recent strategic achievements could deliver longer-term upside, the outlook is constrained until those developments translate into improved profitability and stronger financial stability.

    More about SkinBioTherapeutics

    SkinBioTherapeutics is a life sciences company focused on improving skin health using its proprietary SkinBiotix® platform, developed by researchers at the University of Manchester. Its strategy spans five key pillars across skincare and the gut–skin axis, delivering products both directly to consumers and through retail partners such as Superdrug Stores plc. The company also maintains commercial collaborations, including its partnership with Croda plc.

  • Ocado Receives $350M Payment from Kroger Following CFC Closures

    Ocado Receives $350M Payment from Kroger Following CFC Closures

    Ocado Group (LSE:OCDO) has secured a one-off cash payment of $350 million from Kroger after the U.S. retailer elected to close three Customer Fulfillment Centers (CFCs) and halt development of a planned facility in Charlotte, North Carolina. While the closures reduce the footprint of the network, Ocado continues to support Kroger’s efficiency and growth efforts by rolling out new technologies across the remaining CFCs. This includes the upcoming deployment of the AutoFreezer system at the Phoenix, Arizona site. Ocado expects its fee revenue for FY26 to fall by roughly $50 million as a result of the changes, but the company remains committed to improving cash generation through disciplined cost management and expansion of its solutions.

    Ocado’s outlook remains weighed down by financial pressures, including shrinking revenue and elevated leverage. Technical indicators point to ongoing bearish momentum, and valuation metrics remain weak due to negative earnings. Although recent earnings commentary highlighted better revenue trends and improving liquidity, sustained cost challenges continue to temper sentiment.

    More about Ocado Group

    Ocado Group plc operates at the intersection of online grocery retail and advanced automation. The company provides proprietary robotic fulfillment technology and end-to-end logistics solutions to help retailers enhance efficiency and elevate the online shopping experience. Its technology platform is used by partners globally across diverse markets.

  • Genedrive plc Reports Strong Operational Momentum and Financial Improvement in 2025

    Genedrive plc Reports Strong Operational Momentum and Financial Improvement in 2025

    Genedrive plc (LSE:GDR) has delivered a notable improvement in performance for the year ended June 2025, doubling revenue to £1 million and narrowing its post-tax loss to £5.2 million. The year included several key operational achievements, such as securing CE certification for the Genedrive® CYP2C19 ID Kit, enabling broader commercial rollout across the EU. The test has already been incorporated into multiple NHS initiatives and is in clinical use at centres including Salford Royal Hospital. Genedrive also received a favourable value assessment from Scotland’s Health Technology Group, paving the way for government-backed adoption of pharmacogenetic testing. Meanwhile, the Genedrive® MT-RNR1 ID Kit earned a conditional recommendation from NICE and is now deployed across a growing number of UK hospitals, with further expansion planned. Internationally, the company is advancing regulatory discussions and forging partnerships in the Middle East and the United States to extend its global reach.

    Despite the strong operational progress, Genedrive continues to contend with profitability pressures. Technical indicators point to bearish momentum, and valuation metrics remain stretched due to the lack of earnings. Nonetheless, the company’s recent milestones strengthen its competitive position and could support improved prospects over time.

    More about Genedrive

    Genedrive plc is a UK-based pharmacogenetic testing company focused on developing rapid, affordable, and user-friendly point-of-care diagnostic tools. Its technology helps clinicians tailor medication decisions—particularly in acute care settings—by providing fast, actionable genetic insights. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to support safer and more effective treatment pathways.

  • Iofina to Build New IOsorb® Plant in Permian Basin Through Partnership with Western Midstream

    Iofina to Build New IOsorb® Plant in Permian Basin Through Partnership with Western Midstream

    Iofina plc (LSE:IOF) has entered into a partnership with Western Midstream Partners to construct a new IOsorb® facility in the Permian Basin. The plant will employ Iofina’s WET IOsorb® technology to recover iodine from produced water and is slated to begin operations in the second half of 2026. Once online, it will double the company’s brine-processing capacity to 50,000 barrels per day, making it Iofina’s largest-producing site. Collaborating with Western Midstream — a major player in produced water infrastructure — represents a strategic step in scaling Iofina’s production base and strengthening its foothold in one of the most important oil-producing regions in the United States.

    Iofina’s outlook reflects a sound financial foundation and a valuation that appears broadly reasonable. Still, bearish technical signals and narrowing profitability margins pose challenges that the company will need to address to improve investor sentiment and share performance.

    More about Iofina plc

    Iofina plc is a fully integrated iodine producer and specialty chemical manufacturer, operating as North America’s second-largest iodine supplier. Its subsidiary Iofina Resources develops and runs iodine extraction plants using proprietary WET IOsorb® technology, while Iofina Chemical manufactures a range of halogen-based specialty chemicals for global customers.

  • Unilever Finalises Demerger of Ice Cream Division

    Unilever Finalises Demerger of Ice Cream Division

    Unilever (LSE:ULVR) has completed the separation of its ice cream arm, which will now operate as The Magnum Ice Cream Company N.V. (TMICC). The demerger becomes effective on 6 December 2025, with TMICC shares scheduled to begin trading in Amsterdam, London, and New York on 8 December 2025. As part of the restructuring, Unilever will implement a share consolidation to ensure price continuity, marking a significant step in its broader effort to streamline operations and boost long-term shareholder value.

    Unilever’s investment outlook continues to benefit from strong financial fundamentals and an encouraging earnings trajectory. While certain technical signals and valuation considerations remain mixed, the company’s consistent profitability and growth across developed markets — alongside its strategic expansion in emerging regions — underpin a favourable overall view.

    More about Unilever

    Unilever PLC is a global leader in the consumer goods sector, offering a wide portfolio of products across food, beverages, home care, and personal care categories. The company maintains a broad international footprint and places strong emphasis on sustainability initiatives and product innovation across its brands.

  • London BTC Company Unveils Expansion Plans and Pursues Strategic Growth Initiatives

    London BTC Company Unveils Expansion Plans and Pursues Strategic Growth Initiatives

    London BTC Company Limited (LSE:BTC) has outlined an ambitious expansion of its North American bitcoin mining footprint, targeting an increase to roughly 1,500 ASIC machines in 2026, funded through existing reserves. The company is also evaluating a potential Nasdaq listing as a way to tap larger pools of capital and attract institutional investors. Alongside scaling its mining capacity, London BTC is exploring additional revenue opportunities designed to diversify its income base and enhance returns from its bitcoin holdings. The CEO’s involvement in the Abu Dhabi Bitcoin MENA Conference further highlights the firm’s efforts to deepen global industry ties.

    More about London BTC Company Limited

    London BTC Company Limited is a bitcoin-focused enterprise listed on the London Stock Exchange and trading on the OTCQB in the United States. Its strategy centres on building strategic bitcoin reserves through mining operations located across Indiana, Iowa, Nebraska, Texas, and Labrador in Canada. The company aims to use bitcoin both as a treasury asset and as a tool for broader currency management.